May 1 2020 |
Where’s the Meat? Interim Federal Guidance for Meat Plant Worker Safety |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 13 2023 |
CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 18 2020 |
The Next in the Series of Executive Orders Affecting the Pharmaceutical Industry |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 14 2010 |
Elimination of Customs Duties Possible for Over 700 Additional Pharmaceutical Products and Chemical Intermediates |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 10 2018 |
WARNING: Prop 65 Has Changed – If Your Product Is Sold In California Or You Do Business In California, Pay Attention |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 19 2018 |
WARNING: There Are New Warning Requirements for Imports Sold in California |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 29 2021 |
“Buy American” Update: Essential Medicines May Continue to Come From Abroad (For Now) |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 12 2018 |
Brady v. Bayer Corp: One A Day Will Not Keep Plaintiffs Away |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 20 2018 |
Blog Series Part 7: CMS Proposed Rule on Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Medicaid Fee-For-Service, and Medicaid Managed Care Programs for 2020 and 2021 |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 12 2022 |
FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19 |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 24 2022 |
New York Regulators to Jumpstart NY’s Cannabis Industry by Giving Priority to Small Businesses and Individuals with Prior Cannabis Convictions |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 5 2014 |
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 13 2022 |
French Insider Podcast Episode 14: French Investments in the U.S. Wine Industry [PODCAST] |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 3 2022 |
The Government Seeks FCA Liability for Off-Label Use of Medical Devices |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 17 2015 |
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 19 2019 |
Spate of Recent False Advertising Class Actions Take On Animal Treatment Label Claims |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 6 2022 |
BREAKING NEWS: Biden to Pardon Federal Marijuana Possession Convictions |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 28 2015 |
What’s in a Name? That Which We Call a Biological Product… |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 19 2016 |
Extending Patentable Life of 3D Printers: Lesson From Pharmaceutical Industry |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 14 2023 |
FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 31 2023 |
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 1 2023 |
Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree? |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 11 2023 |
The U.S. Department of Labor Provides Guidance for Agricultural Employers on the PUMP Act |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 15 2017 |
Foreign Investment Under Trump Administration |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 10 2021 |
Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 30 2009 |
OTC Drug and Dietary Supplement Labeling: Adverse Event Reporting Information |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 19 2018 |
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 5 2021 |
California Jury Awards Millions to Cannabis Company in Antitrust Case |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 1 2021 |
Florida Imposes Criminal Penalties for Improper Processing of DNA |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 10 2021 |
CMS Suspends Vaccine Mandate Enforcement for Healthcare Workers |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 3 2022 |
Healthcare Res. Mgmt. Grp., LLC v. Econatura All Healthy World, LLC – A Cautionary Tale: Meticulous or Careless Strategy Required to Prove Your Trade Secret Claim |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2014 |
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 3 2014 |
Northern District of California Courts Still Searching for Sweet Spot in “Evaporated Cane Juice” Cases: Confusion Over Applicability of Primary Jurisdiction to ECJ Claims Continues |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 24 2022 |
HHS OIG Signs Off on Substance Use Recovery Incentive Program |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 4 2014 |
Mobile Health Apps are in a Boom Phase – Why is it so Hard for Pharmaceutical Companies to Find Users? |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 15 2022 |
California Expands FEHA to Include Off The Job Cannabis Use |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 31 2022 |
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 6 2022 |
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 22 2020 |
New Jersey Court Commands Cannabis Reimbursement in Workers’ Compensation Dispute |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 6 2023 |
FDA Clarifies Approach to Pediatric Drug Development |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 7 2020 |
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 14 2016 |
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 18 2020 |
President Of Medical Technology Company Charged For Promoting Fake COVID-19 Treatment |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 11 2021 |
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 18 2021 |
Recent FTC Settlement Serves as Reminder For Digital Health Developers |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 10 2017 |
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 3 2013 |
The Food and Drug Administration (FDA) Releases Long-Awaited Final Guidance on Mobile Medical Applications |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 22 2021 |
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 22 2021 |
FDA Joins Other Regulators in Focus on AI and Machine Learning |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 12 2014 |
Proposed Health Information Technology Strategy Aims to Promote Innovation |
Sheppard, Mullin, Richter & Hampton LLP |